UK stock markets fell for the first time in five days on Tuesday with investors on edge ahead of a looming deadline imposed by the Trump administration to seal a ceasefire deal with Iran.

On an otherwise quiet day for UK corporate releases, oil giant Shell is due to release a first-quarter update on Wednesday, ...

Synergia Energy announced on Tuesday that it has secured a loan facility of up to $700,000 from Republic Investment Management to support its working capital requirements.

US durable goods orders fell for a third consecutive month in February, according to the Census Bureau, as weakness in the transport sector continued to weigh on headline demand.

Ninety One tanked after Bank of America downgraded the shares to ‘neutral’ from ‘buy’ and cut the price target to 260p from 280p, citing lower expected market returns. The news hit other fund managers ...

One Health Group said on Tuesday that it has secured a renewed multi-year contract with Sheffield Teaching Hospital, extending a longstanding partnership and increasing the visibility of its revenue ...

The Elon Musk-led rocket and space technology company reportedly told its banking syndicate that it plans to raise around $75bn, implying a valuation of up to $1.75trn. The roadshow was expected to ...

Berkeley revealed on Tuesday that executive chairman Robert Perrins had acquired 7,000 ordinary shares in the FTSE 100-listed property developer.

BP shareholders have been recommended by proxy advisory firm Glass Lewis to vote against the re-election of chair Albert Manifold, amid claims that he was responsible for excluding a climate-related ...

Richmond Hill Resources announced on Tuesday that it has agreed to acquire the Bartlett Mining Claims in Ontario, Canada, in a related party transaction that would expand its footprint adjacent to the ...

Major indices opened lower on Tuesday following reports that the US ‌military had conducted strikes ​on Iran's ​Kharg Island.

California-based Gilead Sciences said on Tuesday that it has agreed to buy German clinical stage biotechnology group Tubulis for up to $5bn.